Top

Published in:

Open Access 01-12-2015 | Research

Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana

Authors: Francisco F. P. G. Pêra, David L. R. Mutepfa, Ayesha M. Khan, Johann H. Els, Sandiswa Mbewana, Alberdina A. A. van Dijk, Edward P. Rybicki, Inga I. Hitzeroth

Published in: Virology Journal | Issue 1/2015

Abstract

Background

Human rotaviruses are the main cause of severe gastroenteritis in children and are responsible for over 500 000 deaths annually. There are two live rotavirus vaccines currently available, one based on human rotavirus serotype G1P[8], and the other a G1-G4 P[8] pentavalent vaccine. However, the recent emergence of the G9 and other novel rotavirus serotypes in Africa and Asia has prompted fears that current vaccines might not be fully effective against these new varieties.

Results

We report an effort to develop an affordable candidate rotavirus vaccine against the new emerging G9P[6] (RVA/Human-wt/ZAF/GR10924/1999/G9P[6]) strain. The vaccine is based on virus-like particles which are both highly immunogenic and safe. The vaccine candidate was produced in Nicotiana benthamiana by transient expression, as plants allow rapid production of antigens at lower costs, without the risk of contamination by animal pathogens. Western blot analysis of plant extracts confirmed the successful expression of two rotavirus capsid proteins, VP2 and VP6. These proteins assembled into VLPs resembling native rotavirus particles when analysed by transmission electron microscopy (TEM). Expression of the rotavirus glycoprotein VP7 and the spike protein VP4 was also tried. However, VP7 expression caused plant wilting during the course of the time trial and expression could never be detected for either protein. We therefore created three fusion proteins adding the antigenic part of VP4 (VP8*) to VP6 in an attempt to produce more appropriately immunogenic particles. Fusion protein expression in tobacco plants was detected by western blot using anti-VP6 and anti-VP4 antibodies, but no regular particles were observed by TEM, even when co-expressed with VP2.

Conclusion

Our results suggest that the rotavirus proteins produced in N. benthamiana are candidates for a subunit vaccine specifically for the G9P[6] rotavirus strain. This could be more effective in developing countries, thereby possibly providing a higher overall efficacy for the existing vaccines. The production of rotavirus proteins in plants would probably result in lower manufacturing costs, making it more affordable for developing countries. Further investigation is required to evaluate the immunogenic potential of the VLPs and fusion proteins created in this study.

Available only for authorised users

Bishop RF, Davidson GP. Virus-particles in epithelial-cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet. 1973;2(7841):1281–3.CrossRefPubMed

Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565–72.PubMedCentralCrossRefPubMed

Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136–41. doi:10.1016/S1473-3099.CrossRefPubMed

Waggie Z, Hawkridge A, Hussey GD. Review of rotavirus studies in Africa: 1976–2006. J Infect Dis. 2010;202(Supplement 1):S23–33.CrossRefPubMed

Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81(3):197–204.PubMedCentralPubMed

Walker CLF, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Childhood pneumonia and diarrhoea 1 global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–16. doi:10.1016/S0140-6736.CrossRefPubMed

Ruiz MC, Leon T, Diaz Y, Michelangeli F. Molecular biology of rotavirus entry and replication. Sci World J. 2009;9:1476–97. doi:10.1100/tsw.2009.158.CrossRef

Wen X, Cao D, Jones RW, Li J, Szu S, Hoshino Y. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine. 2012;30(43):6121–6. doi:10.1016/j.vaccine.2012.07.078.PubMedCentralCrossRefPubMed

Lentz EM, Mozgovoj MV, Bellido D, Dus Santos MJ, Wigdorovitz A, Bravo-Almonacid FF. VP8* antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model. J Biotechnol. 2011;156(2):100–7.CrossRefPubMed

10.

Matthijnssens J, Otto P, Ciarlet M, Desselberger U, Van Ranst M, Johne R. VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol. 2012;157(6):1177–82. doi:10.1007/s00705-012-1273-3.CrossRefPubMed

11.

Jere KC, Mlera L, O’Neill HG, Potgieter AC, Page NA, Seheri ML, et al. Whole genome analyses of African G2, G8, G9, and G12 rotavirus strains using sequence-independent amplification and 454 (R) pyrosequencing. J Med Virol. 2011;83(11):2018–42. doi:10.1002/Jmv.22207.CrossRefPubMed

12.

Hoshino Y, Kapikian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr. 2000;18(1):5–14.PubMed

13.

Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Banyai K, Brister JR, et al. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol. 2011;156(8):1397–413.PubMedCentralCrossRefPubMed

14.

Matthijnssens J, Mino S, Papp H, Potgieter C, Novo L, Heylen E, et al. Complete molecular genome analyses of equine rotavirus A strains from different continents reveal several novel genotypes and a largely conserved genotype constellation. J Gen Virol. 2012;93(Pt 4):866–75.CrossRefPubMed

15.

Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368(9532):323–32.CrossRefPubMed

16.

Page N, Esona M, Armah G, Nyangao J, Mwenda J, Sebunya T, et al. Emergence and characterization of serotype G9 rotavirus strains from Africa. J Infect Dis. 2010;202(Suppl):S55–63.CrossRefPubMed

17.

Todd S, Page NA, Duncan SA, Peenze I, Cunliffe NA. Rotavirus strain types circulating in Africa: Review of studies published during 1997–2006. J Infect Dis. 2010;202(Suppl):S34–42.CrossRefPubMed

18.

Seheri LM, Page N, Dewar JB, Geyer A, Nemarude AL, Bos P, et al. Characterization and molecular epidemiology of rotavirus strains recovered in Northern Pretoria, South Africa during 2003–2006. J Infect Dis. 2010;202(Supplement 1):S139–47.CrossRefPubMed

19.

Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996–1999: emergence of G9 strains and P[6] strains. Vaccine. 2003;21:361–7. doi:10.1016/s0264.CrossRefPubMed

20.

Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl J Med. 2010;362(4):289–98. doi:10.1056/Nejmoa0904797.CrossRefPubMed

21.

Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–14. doi:10.1016/s0140-6736(10)60889-6.CrossRefPubMed

22.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006;24(22):4821–9.CrossRefPubMed

23.

Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B et al. Human rotavirus vaccine Rotarix (TM) provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012;12. Doi 10.1186/1471-2334-12-213

24.

Babji S, Kang G. Rotavirus vaccination in developing countries. Curr Opin Virol. 2012;2(4):443–8. doi:10.1016/j.coviro.2012.05.005.CrossRefPubMed

25.

Potgieter AC, Page NA, Liebenberg J, Wright IM, Landt O, van Dijk AA. Improved strategies for sequence-independent amplification and sequencing of viral double-stranded RNA genomes. J Gen Virol. 2009;90(Pt 6):1423–32.CrossRefPubMed

26.

Hemming M, Vesikari T. Vaccine derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J. 2012;31:992.CrossRefPubMed

27.

El-Attar L, Oliver SL, Mackie A, Charpilienne A, Poncet D, Cohen J, et al. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine. 2009;27(24):3201–8.CrossRefPubMed

28.

Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 1994;68(9):5945–52.PubMedCentralPubMed

29.

Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine. 2003;21(25–26):3885–900.CrossRefPubMed

30.

Rodriguez-Limas WA, Tyo KE, Nielsen J, Ramirez OT, Palomares LA. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact. 2011;10:33.PubMedCentralCrossRefPubMed

31.

Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J. 2010;8(5):620–37.CrossRefPubMed

32.

Matsumura T, Itchoda N, Tsunemitsu H. Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. Arch Virol. 2002;147(6):1263–70.CrossRefPubMed

33.

O’Brien GJ, Bryant CJ, Voogd C, Greenberg HB, Gardner RC, Bellamy AR. Rotavirus VP6 expressed by PVX vectors in Nicotiana benthamiana coats PVX rods and also assembles into viruslike particles. Virology. 2000;270(2):444–53.CrossRefPubMed

34.

Zhou B, Zhang Y, Wang X, Dong J, Wang B, Han C, et al. Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. Vaccine. 2010;28(37):6021–7.CrossRefPubMed

35.

Saldana S, Esquivel GF, Olivera Flores TJ, Arias N, Lopez S, Arias C, et al. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. Viral Immunol. 2006;19(1):42–53.CrossRefPubMed

36.

Takeda A, Sugiyama K, Nagano H, Mori M, Kaido M, Mise K, et al. Identification of a novel RNA silencing suppressor, NSs protein of Tomato spotted wilt virus. FEBS Lett. 2002;532(1–2):75–9.CrossRefPubMed

37.

Emslie KR, Miller JM, Slade MB, Dormitzer PR, Greenberg HB, Williams KL. Expression of the rotavirus SA11 protein VP7 in the simple eukaryote Dictyostelium discoideum. J Virol. 1995;69(3):1747–54.PubMedCentralPubMed

38.

McCrae MA, McCorquodale JG. Expression of a major bovine rotavirus neutralisation antigen (VP7c) in Escherichia coli. Gene. 1987;55(1):9–18.CrossRefPubMed

39.

Maass DR, Atkinson PH. Retention by the endoplasmic reticulum of rotavirus VP7 is controlled by three adjacent amino-terminal residues. J Virol. 1994;68(1):366–78.PubMedCentralPubMed

40.

Zambrano JL, Diaz Y, Pena F, Vizzi E, Ruiz MC, Michelangeli F, et al. Silencing of rotavirus NSP4 or VP7 expression reduces alterations in Ca2+ homeostasis induced by infection of cultured cells. J Virol. 2008;82(12):5815–24. doi:10.1128/JVI.02719-07.PubMedCentralCrossRefPubMed

41.

Perez JF, Chemello ME, Liprandi F, Ruiz MC, Michelangeli F. Oncosis in MA104 cells is induced by rotavirus infection through an increase in intracellular Ca2+ concentration. Virology. 1998;252(1):17–27.CrossRefPubMed

42.

Choi NW, Estes MK, Langridge WH. Synthesis and assembly of a cholera toxin B subunit-rotavirus VP7 fusion protein in transgenic potato. Mol Biotechnol. 2005;31(3):193–202.CrossRefPubMed

43.

Li JT, Fei L, Mou ZR, Wei J, Tang Y, He HY, et al. Immunogenicity of a plant-derived edible rotavirus subunit vaccine transformed over fifty generations. Virology. 2006;356(1–2):171–8.CrossRefPubMed

44.

Wu YZ, Li JT, Mou ZR, Fei L, Ni B, Geng M, et al. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology. 2003;313(2):337–42.CrossRefPubMed

45.

Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, et al. Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol. 2015;87(1):102–11. doi:10.1002/jmv.23973.CrossRefPubMed

46.

Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine. 2008;26(35):4594–601. doi:10.1016/j.vaccine.2008.05.089.CrossRefPubMed

47.

Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol. 2006;80(4):1752–61. doi:10.1128/jvi.80.4.1752-1761.2006.PubMedCentralCrossRefPubMed

48.

Kovacs-Nolan J, Mine Y. Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice. Biochim Biophys Acta Gen Subj. 2006;1760(12):1884–93. doi:10.1016/j.bbagen.2006.07.015.CrossRef

49.

Lepault J. Structural polymorphism of the major capsid protein of rotavirus. EMBO J. 2001;20(7):1498–507. doi:10.1093/emboj/20.7.1498.PubMedCentralCrossRefPubMed

50.

Petitpas I, Lepault J, Vachette P, Charpilienne A, Mathieu M, Kohli E, et al. Crystallization and preliminary X-Ray analysis of rotavirus protein VP6. J Virol. 1998;72(9):7615–9.PubMedCentralPubMed

51.

Vieira HL, Estevao C, Roldao A, Peixoto CC, Sousa MF, Cruz PE, et al. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol. 2005;120(1):72–82.CrossRefPubMed

52.

Saldaña S, Guadarrama FE, Flores TDJO, Arias N, López S, Arias C, et al. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of Capsid proteins VP2 and VP6 and immunological studies. Viral Immunol. 2006;19(1):42–53. doi:10.1089/vim.2006.19.42.CrossRefPubMed

53.

Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, et al. Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J. 2011;8(1):3. doi:10.1186/1743-422x-8-3.PubMedCentralCrossRefPubMed

54.

Yuan L, Geyer A, Hodgins DC, Fan Z, Qian Y, Chang KO, et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol. 2000;74(19):8843–53.PubMedCentralCrossRefPubMed

55.

Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996;174(Supplement 1):S88–92. doi:10.1093/infdis/174.supplement_1.s88.CrossRefPubMed

56.

Crawford SE, Estes MK, Ciarlet M, Barone C, O’Neal CM, Cohen J, et al. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol. 1999;73(6):4813–22.PubMedCentralPubMed

57.

Klose J, Wendt N, Kubald S, Krause E, Fechner K, Beyermann M, et al. Hexa-histidin tag position influences disulfide structure but not binding behavior of in vitro folded N-terminal domain of rat corticotropin-releasing factor receptor type 2a. Protein Sci. 2004;13(9):2470–5. doi:10.1110/ps.04835904.PubMedCentralCrossRefPubMed

58.

Chant A, Kraemer-Pecore CM, Watkin R, Kneale GG. Attachment of a histidine tag to the minimal zinc finger protein of the Aspergillus nidulans gene regulatory protein AreA causes a conformational change at the DNA-binding site. Protein Expr Purif. 2005;39(2):152–9. doi:10.1016/j.pep.2004.10.017.CrossRefPubMed

59.

Wang J, Lin Y, Cai P, Wang H. Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens. Protein Pept Lett. 2011;18(1):73–83.CrossRefPubMed

60.

Maclean J, Koekemoer M, Olivier AJ, Stewart D, Hitzeroth II, Rademacher T, et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol. 2007;88(Pt 5):1460–9.CrossRefPubMed

61.

Sainsbury F, Lomonossoff GP. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol. 2008;148(3):1212–8. doi:10.1104/pp.108.126284.PubMedCentralCrossRefPubMed

62.

Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J. 2010;8(1):38–46. doi:10.1111/j.1467-7652.2009.00462.x.CrossRefPubMed

63.

Prins M, Resende RD, Anker C, VanSchepen A, DeHaan P, Goldbach R. Engineered RNA-mediated resistance to tomato spotted wilt virus is sequence specific. Mol Plant Microbe. 1996;9(5):416–8. doi:10.1094/Mpmi-9-0416.CrossRef

Title: Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana
Authors: Francisco F. P. G. Pêra
David L. R. Mutepfa
Ayesha M. Khan
Johann H. Els
Sandiswa Mbewana
Alberdina A. A. van Dijk
Edward P. Rybicki
Inga I. Hitzeroth
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2015
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-015-0436-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Serological survey of canine H3N2, pandemic H1N1/09, and human seasonal H3N2 influenza viruses in cats in northern China, 2010–2014

The HBx oncoprotein of hepatitis B virus potentiates cell transformation by inducing c-Myc-dependent expression of the RNA polymerase I transcription factor UBF

Increased frequency of follicular helper T cells in mice viral myocarditis is relevant with anti-ANT antoantibody

Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know?

Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І

Patient-derived hepatitis C virus inhibits CD4+ but not CD8+ T lymphocyte proliferation in primary T cells

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage